Skip to content Skip to footer
Subscribe Now
NEWS

Kairos Pharma Reports Positive Interim P-II Data for ENV-105 in Metastatic Prostate Cancer

Shots: Kairos Pharma announced positive interim efficacy data from its ongoing P-II study evaluating ENV-105 (carotuximab) in combination with apalutamide in pts. with metastatic castration-resistant prostate cancer (mCRPC) The combination demonstrated a statistically significant improvement in progression-free survival, with median PFS of 17.7 mons. vs 2 mons. with apalutamide alone (P=0.0008) Following the interim results,…
3 days ago

Read more

Genmab and AbbVie
NEWS

AbbVie and Genmab Report Positive Data from the P-III Study of Epcoritamab Plus R-CHOP in Newly Diagnosed DLBCL

Shots: AbbVie and Genmab announced positive topline results from the P-III (EPCORE DLBCL-2) study, demonstrating a statistically significant and clinically meaningful improvement in PFS vs R-CHOP alone (SoC) in newly diagnosed diffuse large B-cell lymphoma (DLBCL) pts. with an IPI score of 2-5 The study evaluated fixed treatment duration epcoritamab(SC) plus rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and…
3 days ago

Read more

NEWS

Merck and SciBrunch Sign ~$2.13B Exclusive Global License Agreement for SPR2015

Shots: Merck & SciBrunch have entered into an exclusive global license agreement for SPR2015, with Merck receiving exclusive rights to develop, manufacture & commercialize SPR2015 worldwide As per the deal, SciBrunch will receive ~$400M upfront & payment associated with development, commercialization & other milestones across multiple indications, representing the total deal value of ~$2.13B SPR2015…
September 28, 2026

Read more

NEWS

Earendil Labs Inks $1.5B+ Research Collaboration with Genentech to Advance Bispecific Antibodies in Oncology

Shots: Earendil Labs has entered into a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology Earendil Labs will lead antibody discovery & research through early clinical development for programs targeting certain pre-agreed target combinations, while Genentech will take over global clinical development & commercialization As per the deal,…
September 24, 2026

Read more

NEWS

Astellas Reports First Patient Dosing in P-III Study of Setidegrasib in Previously Treated KRAS G12D-Mutated NSCLC

Shots: Astellas has dosed the first patient in a P-III study assessing setidegrasib vs docetaxel in ~356 pts with KRAS G12D-mutated locally advanced (unresectable) or metastatic NSCLC who progressed on or after initial Pt-based CT & checkpoint inhibitor therapy The P-III study in previously treated NSCLC builds on P-I data published in The NEJM in Mar…
September 24, 2026

Read more

NEWS

Envisagenics and Boehringer Ingelheim Sign >$1B Cancer Drug Development Deal

Shots: Envisagenics has entered a multi-year research collaboration & option agreement with BI to validate tumor-specific targets for developing first-in-class precision therapies for solid tumors, using Envisagenics’ AI-powered SpliceCore platform  Collaboration builds on targets identified through SpliceCore to validate their potential across ADCs, TCEs & multispecific Abs, with BI having an option to exclusively license…
September 23, 2026

Read more

NEWS

Shilpa Biologicals and SPIMACO Bio Partner to Advance Access to PD-1 Inhibitor Biosimilars in MENA Region  

Shots:  Shilpa Biologicals has entered into an exclusive MENA licensing & commercialization agreement with SPIMACO Bio for a portfolio of PD-1 inhibitor biosimilars used in cancer immunotherapy  Shilpa Biologicals will lead exclusive development & manufacturing, with phased technology transfer to enable local biosimilar production in Saudi Arabia, while SPIMACO Bio will handle regulatory execution, market…
September 15, 2026

Read more

NEWS

Cipla Partners with Qilu Pharmaceutical to Commercialize QL2107 (Biosimilar, Keytruda) in the US

Shots: Invagen Pharmaceuticals, a wholly owned subsidiary of Cipla, has entered into a strategic partnership with Qilu Pharmaceutical for the exclusive licensing & supply of QL2107, a biosimilar version of Keytruda (pembrolizumab), for the US As per the deal, Qilu will handle product development, regulatory registration & supply, while Cipla USA will commercialize the asset across the…
September 4, 2026

Read more

Load more